A few posts ago, the FEHBlog favorably mentioned the National COVID-19 Convalescent Plasma Project. “Researchers hope transfusions of antibody-rich plasma from recovered Covid-19 patients can help neutralize the coronavirus in patients who are sick.” Today the Wall Street Journal reports that
A [Phase 2] study of thousands of Covid-19 patients who received blood plasma transfusions from recovered patients indicates the experimental therapy appears to be safe, paving the way for future studies and clinical trials.
A team of researchers at Mayo Clinic, Michigan State University and Johns Hopkins University examined health outcomes of 5,000 hospitalized patients around the U.S. who received convalescent plasma treatment, and found the transfusions resulted in few serious side effects and there wasn’t an excessive mortality rate.
Let’s go.
In other upbeat news, the Wall Street Journal reports that “More patients are turning to mail or courier to get their prescription drugs during coronavirus lockdowns, a shift from the traditional visit with a pharmacist that is expected to endure after the pandemic subsides.” Mail order delivery of maintenance medications is known to create a cost savings for health plans and their members.
Health Payer Intelligence discusses a fascinating PriceWaterHouseCoopers healthcare consumer survey conducted during the great hunkering down. The survey’s “results signal that US businesses could play an even bigger role in protecting the health of their workers, that the health system likely will make more room for telehealth and other forms of virtual care, and that the American consumer may take a more active role in managing health and participating in a system that is being remade.”
In other news —
- The FEHBlog ran across this American Medical Association website of its COVID-19 resources.
- Fierce Healthcare calls to our attention the Medscape Physician Compensation Report 2020. “Primary care docs brought in about $243,000, up 2.5% from $237,000 reported a year earlier. Specialists earned about $346,000 on average, up 1.5% from the $341,000 they made a year earlier.”
- OPM issued additional COVID-19 guidance to federal agencies today. It’s not FEHBP related.